(Q46765992)

25 December 2017

title

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment (English)

1 reference

25 December 2017

0 references

1 reference

Ryan Z Turncliff

1

1 reference

25 December 2017

Joi L Dunbar

2

1 reference

25 December 2017

Qunming Dong

3

1 reference

25 December 2017

Bernard L Silverman

4

1 reference

25 December 2017

Elliot W Ehrich

5

1 reference

25 December 2017

Stacy C Dilzer

6

1 reference

25 December 2017

Kenneth C Lasseter

7

1 reference

25 December 2017

publication date

1 November 2005

1 reference

25 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

25 December 2017

volume

45

1 reference

25 December 2017

issue

11

1 reference

25 December 2017

page(s)

1259-1267

1 reference

25 December 2017

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Patients with alcohol problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Mortality and morbidity attributable to use of addictive substances in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Adherence to pharmacotherapy in patients with alcohol and opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

Effect of liver cirrhosis on the systemic availability of naltrexone in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005280199

21 January 2018

Identifiers

DOI

10.1177/0091270005280199

1 reference

25 December 2017

1 reference

25 December 2017